Dr. Sultan Darvesh, neurologist, medicinal chemist, and Treventis founder was as an invited lecturer to the 58th annual Canadian Association of Neuropathogists (CANP), held in Halifax, Nova Scotia on October 4, 2018.
Dr. Darvesh delivered a lecture entitled “Butyrylcholinesterase as a Biomarker for Alzheimer’s Disease” in which he explained the neuropathology of butyrylcholinesterase. He also presented data on the specificity and sensitivity of butyrylcholinesterase as a biomarker for Alzheimer’s disease.
A medicinal chemist, neuroscientist, and behavioral neurologist practicing in Halifax, Sultan Darvesh is head of Treventis Diagnostics and the Irene MacDonald Sobey Chair in Curative Approaches to Alzheimer’s Disease. He is an acknowledged expert in the pathology of Alzheimer’s disease and particularly in the role of cholinesterases and their role in neurological health and disease. His laboratory specializes in the design and synthesis of radiotracer small molecules that can be used in non-invasive brain imaging to pinpoint areas of abnormal function in brain diseases. He also serves as director of the Maritime Brain Tissue Bank.